Legato Capital Management LLC Purchases 476 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Legato Capital Management LLC increased its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 2.1% in the fourth quarter, Holdings Channel reports. The institutional investor owned 23,178 shares of the medical instruments supplier’s stock after buying an additional 476 shares during the period. Legato Capital Management LLC’s holdings in LeMaitre Vascular were worth $2,136,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of the company. NBC Securities Inc. boosted its position in LeMaitre Vascular by 73.2% during the 3rd quarter. NBC Securities Inc. now owns 433 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 183 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of LeMaitre Vascular by 34.3% in the third quarter. GAMMA Investing LLC now owns 736 shares of the medical instruments supplier’s stock worth $68,000 after purchasing an additional 188 shares in the last quarter. KBC Group NV boosted its holdings in LeMaitre Vascular by 58.4% during the fourth quarter. KBC Group NV now owns 1,112 shares of the medical instruments supplier’s stock worth $102,000 after purchasing an additional 410 shares during the last quarter. Empowered Funds LLC bought a new position in LeMaitre Vascular in the fourth quarter valued at $150,000. Finally, SG Americas Securities LLC acquired a new stake in LeMaitre Vascular in the 4th quarter valued at $158,000. 84.64% of the stock is currently owned by institutional investors.

Insider Buying and Selling at LeMaitre Vascular

In other news, Director Bridget A. Ross sold 3,750 shares of the stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $101.47, for a total value of $380,512.50. Following the transaction, the director now directly owns 2,278 shares of the company’s stock, valued at $231,148.66. This represents a 62.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 10.79% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on LMAT. Barrington Research increased their price objective on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a research note on Friday, November 1st. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a research note on Friday, December 13th. Oppenheimer reiterated an “outperform” rating and set a $93.00 price objective (up previously from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Finally, Cantor Fitzgerald started coverage on shares of LeMaitre Vascular in a research note on Tuesday, October 15th. They issued a “neutral” rating and a $96.00 target price for the company. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $94.57.

LeMaitre Vascular Trading Down 1.5 %

Shares of NASDAQ LMAT opened at $96.94 on Wednesday. The company has a market capitalization of $2.18 billion, a P/E ratio of 52.97, a P/E/G ratio of 2.19 and a beta of 0.96. LeMaitre Vascular, Inc. has a 12 month low of $58.66 and a 12 month high of $109.58. The stock has a 50 day moving average of $96.43 and a 200-day moving average of $93.37.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.